Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 receptor. They are more aggressive than other breast cancer subtypes, with a higher mean tumor size, higher tumor grade, the worst f...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/8/1207 |
| _version_ | 1797585397503492096 |
|---|---|
| author | Abygail G. Chapdelaine Gongqin Sun |
| author_facet | Abygail G. Chapdelaine Gongqin Sun |
| author_sort | Abygail G. Chapdelaine |
| collection | DOAJ |
| description | Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 receptor. They are more aggressive than other breast cancer subtypes, with a higher mean tumor size, higher tumor grade, the worst five-year overall survival, and the highest rates of recurrence and metastasis. Developing targeted therapies for TNBC has been a major challenge due to its heterogeneity, and its treatment still largely relies on surgery, radiation therapy, and chemotherapy. In this review article, we review the efforts in developing targeted therapies for TNBC, discuss insights gained from these efforts, and highlight potential opportunities going forward. Accumulating evidence supports TNBCs as multi-driver cancers, in which multiple oncogenic drivers promote cell proliferation and survival. In such multi-driver cancers, targeted therapies would require drug combinations that simultaneously block multiple oncogenic drivers. A strategy designed to generate mechanism-based combination targeted therapies for TNBC is discussed. |
| first_indexed | 2024-03-11T00:05:34Z |
| format | Article |
| id | doaj.art-912ff21796cb459caf4cc9cc6661dce4 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T00:05:34Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-912ff21796cb459caf4cc9cc6661dce42023-11-19T00:23:44ZengMDPI AGBiomolecules2218-273X2023-08-01138120710.3390/biom13081207Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast CancerAbygail G. Chapdelaine0Gongqin Sun1Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI 02881, USADepartment of Cell and Molecular Biology, University of Rhode Island, Kingston, RI 02881, USATriple negative breast cancer (TNBC) is a heterogeneous group of breast cancers characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 receptor. They are more aggressive than other breast cancer subtypes, with a higher mean tumor size, higher tumor grade, the worst five-year overall survival, and the highest rates of recurrence and metastasis. Developing targeted therapies for TNBC has been a major challenge due to its heterogeneity, and its treatment still largely relies on surgery, radiation therapy, and chemotherapy. In this review article, we review the efforts in developing targeted therapies for TNBC, discuss insights gained from these efforts, and highlight potential opportunities going forward. Accumulating evidence supports TNBCs as multi-driver cancers, in which multiple oncogenic drivers promote cell proliferation and survival. In such multi-driver cancers, targeted therapies would require drug combinations that simultaneously block multiple oncogenic drivers. A strategy designed to generate mechanism-based combination targeted therapies for TNBC is discussed.https://www.mdpi.com/2218-273X/13/8/1207triple negative breast cancertargeted therapymulti-driver oncogenesiscombination targeted therapy |
| spellingShingle | Abygail G. Chapdelaine Gongqin Sun Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer Biomolecules triple negative breast cancer targeted therapy multi-driver oncogenesis combination targeted therapy |
| title | Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer |
| title_full | Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer |
| title_fullStr | Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer |
| title_full_unstemmed | Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer |
| title_short | Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer |
| title_sort | challenges and opportunities in developing targeted therapies for triple negative breast cancer |
| topic | triple negative breast cancer targeted therapy multi-driver oncogenesis combination targeted therapy |
| url | https://www.mdpi.com/2218-273X/13/8/1207 |
| work_keys_str_mv | AT abygailgchapdelaine challengesandopportunitiesindevelopingtargetedtherapiesfortriplenegativebreastcancer AT gongqinsun challengesandopportunitiesindevelopingtargetedtherapiesfortriplenegativebreastcancer |